Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MIRM
stocks logo

MIRM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
135.72M
+36.52%
-0.063
-87.08%
141.61M
+26.91%
0.000
-100%
147.88M
+15.73%
0.040
-133.33%
Estimates Revision
The market is revising Upward the revenue expectations for Mirum Pharmaceuticals, Inc. (MIRM) for FY2025, with the revenue forecasts being adjusted by 0.71% over the past three months. During the same period, the stock price has changed by -5.96%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-51.42%
In Past 3 Month
Stock Price
Go Down
down Image
-5.96%
In Past 3 Month
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 71.530
sliders
Low
77.00
Averages
88.11
High
95.00
Current: 71.530
sliders
Low
77.00
Averages
88.11
High
95.00
Cantor Fitzgerald
Overweight
maintain
$85 -> $95
2025-11-05
Reason
Cantor Fitzgerald
Price Target
$85 -> $95
2025-11-05
maintain
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Mirum Pharmaceuticals to $95 from $85 and keeps an Overweight rating on the shares. This was a profitable quarter for Mirum as it gradually transitions to an earnings growth story, and Cantor expects considerable inflection in EPS in 2027 and beyond, the analyst tells investors in a research note.
Citizens JMP
Outperform
maintain
$81 -> $95
2025-11-05
Reason
Citizens JMP
Price Target
$81 -> $95
2025-11-05
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Mirum Pharmaceuticals to $95 from $81 and keeps an Outperform rating on the shares. Livmarli delivered another strong quarter of sales as focus is set to shift to the pivotal volixibat data in primary sclerosing cholangitis coming in the second half of 2026, the analyst tells investors in a research note. Mirum remains one of the firm's favorite names in smid-cap biotech, with the stock up 70% year-to-date and poised for further growth on Livmarli's commercial growth, path to profitability, and multiple late-stage clinical readouts starting next year in PSC.
H.C. Wainwright
Swayampakula Ramakanth
Buy
maintain
$80 -> $81
2025-11-05
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$80 -> $81
2025-11-05
maintain
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Mirum Pharmaceuticals to $81 from $80 and keeps a Buy rating on the shares. The company reported a "solid beat and raise quarter," the analyst tells investors in a research note.
Morgan Stanley
NULL -> Overweight
maintain
$75 -> $81
2025-10-16
Reason
Morgan Stanley
Price Target
$75 -> $81
2025-10-16
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Mirum Pharmaceuticals to $81 from $75 and keeps an Overweight rating on the shares. For volixibat, which the firm believes "could drive the next wave of growth," it expects focus to be on comments related to Phase 2b Primary Sclerosing Cholangitis data expected in Q2 of 2026 and the Phase 2b study in Primary Biliary Cholangitis that is expected to complete enrollment next year, the analyst tells investors in a preview.
TD Cowen
NULL -> Buy
initiated
$95
2025-09-24
Reason
TD Cowen
Price Target
$95
2025-09-24
initiated
NULL -> Buy
Reason
TD Cowen initiated coverage of Mirum Pharmaceuticals with a Buy rating and $95 price target. The company has three approved products for rare liver diseases, which are demonstrating strong sales growth, the analyst tells investors in a research note. The firm says Mirum is also advancing volixibat for the treatment of pruritus. TD sees near- and long-term growth with pipeline optionality for the company.
JPMorgan
Overweight
maintain
$53 -> $77
2025-09-12
Reason
JPMorgan
Price Target
$53 -> $77
2025-09-12
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Mirum Pharmaceuticals to $77 from $53 and keeps an Overweight rating on the shares. The firm "meaningfully" increased its Livmarli forecasts following the company's "strong" Q2 beat. With potentially registrational data for volixibat in primary sclerosing cholangitis in Q2 of 2026, Mirum shares have further upside should the trial prove successful, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM.O) is 932.59, compared to its 5-year average forward P/E of 11.67. For a more detailed relative valuation and DCF analysis to assess Mirum Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
11.67
Current PE
932.59
Overvalued PE
197.12
Undervalued PE
-173.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
58.42
Undervalued EV/EBITDA
-87.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.82
Current PS
0.00
Overvalued PS
10.59
Undervalued PS
3.05
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MIRM News & Events

Events Timeline

(ET)
2025-12-01
09:20:00
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study for MRM-3379 in Fragile X Syndrome
select
2025-11-04 (ET)
2025-11-04
17:01:54
Mirum Pharmaceuticals announces Q3 EPS of 5 cents, falling short of consensus estimate of 16 cents.
select
2025-09-08 (ET)
2025-09-08
08:21:23
Mirum Pharmaceuticals finishes enrolling participants in the VISTAS study for volixibat.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Yahoo Finance
Insider at Mirum Pharmaceuticals Offloads $3.7 Million in Shares, Recent SEC Filing Reveals

  • Sale of Shares: Michael G Grey, the Director of Mirum Pharmaceuticals, sold 50,000 shares of the company on December 1, 2025.

  • Company Information: The shares sold were part of Mirum Pharmaceuticals (MIRM), indicating a significant transaction involving company stock.

[object Object]
Preview
9.0
12-01Businesswire
Mirum Pharmaceuticals Initiates BLOOM Phase 2 Study for MRM-3379 in Fragile X Syndrome
  • Clinical Trial Launch: Mirum Pharmaceuticals has announced the enrollment of the first participant in the BLOOM Phase 2 clinical study, evaluating the potential of MRM-3379 to improve cognition and daily function in patients with Fragile X Syndrome, marking a significant advancement in treatment options for this condition.
  • Patient Population Impact: Fragile X Syndrome is the most common inherited intellectual disability, affecting approximately 50,000 males in the U.S. and E.U., and with no approved therapies currently available, the research on MRM-3379 could provide a new treatment avenue for this underserved population.
  • Study Design Details: The study will randomly assign male participants aged 16 to 45 to receive one of three doses of MRM-3379 or a placebo for 12 weeks, assessing safety and tolerability while also exploring effects in younger patients, demonstrating a commitment to addressing the needs of different age groups.
  • Industry Outlook: Given the lack of effective treatments for Fragile X Syndrome, the clinical study of MRM-3379 not only brings hope to patients but also has the potential to significantly enhance Mirum Pharmaceuticals' market position in the rare disease sector.
[object Object]
Preview
8.0
11-24NASDAQ.COM
Options Trading for Mirum Pharmaceuticals (MIRM) in the First Week of July 2026

  • Put Contract Analysis: The $70.00 put contract for MIRM has a bid of $6.00, allowing investors to buy shares at an effective cost of $64.00, which is a 3% discount from the current price of $71.81. There is a 61% chance the contract may expire worthless, potentially yielding an 8.57% return on cash commitment.

  • Call Contract Strategy: The $75.00 call contract has a bid of $6.00, and if shares are purchased at $71.81 and the call is sold, it could yield a total return of 12.80% if exercised by July 2026. There is a 47% chance this contract may also expire worthless, allowing the investor to keep both the shares and the premium.

  • YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing an 8.57% return and the call offering an 8.36% boost, translating to annualized returns of 13.32% and 12.98%, respectively.

  • Volatility Insights: The implied volatility for the put contract is 43% and for the call contract is 41%, while the actual trailing twelve-month volatility is calculated at 38%, indicating a stable trading environment for MIRM.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

The current price of MIRM is 71.53 USD — it has increased 0.76 % in the last trading day.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM)'s business?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

arrow icon

What is the price predicton of MIRM Stock?

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 88.11 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM)'s revenue for the last quarter?

Mirum Pharmaceuticals Inc revenue for the last quarter amounts to 133.01M USD, increased 47.17 % YoY.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM)'s earnings per share (EPS) for the last quarter?

Mirum Pharmaceuticals Inc. EPS for the last quarter amounts to 0.05 USD, decreased -116.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mirum Pharmaceuticals Inc (MIRM)'s fundamentals?

The market is revising Upward the revenue expectations for Mirum Pharmaceuticals, Inc. (MIRM) for FY2025, with the revenue forecasts being adjusted by 0.71% over the past three months. During the same period, the stock price has changed by -5.96%.
arrow icon

How many employees does Mirum Pharmaceuticals Inc (MIRM). have?

Mirum Pharmaceuticals Inc (MIRM) has 322 emplpoyees as of December 05 2025.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM) market cap?

Today MIRM has the market capitalization of 3.68B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free